|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM209746068 |
| 003 |
DE-627 |
| 005 |
20231224010355.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2012 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2011.05.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0699.xml
|
| 035 |
|
|
|a (DE-627)NLM209746068
|
| 035 |
|
|
|a (NLM)21733757
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Warnke, Clemens
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Cladribine as a therapeutic option in multiple sclerosis
|
| 264 |
|
1 |
|c 2012
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.03.2012
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2011. Published by Elsevier Inc.
|
| 520 |
|
|
|a There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a Cladribine
|2 NLM
|
| 650 |
|
7 |
|a 47M74X9YT5
|2 NLM
|
| 700 |
1 |
|
|a Leussink, Verena I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Goebels, Norbert
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aktas, Orhan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Boyko, Alexey
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kieseier, Bernd C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hartung, Hans-Peter
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 142(2012), 1 vom: 15. Jan., Seite 68-75
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:142
|g year:2012
|g number:1
|g day:15
|g month:01
|g pages:68-75
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2011.05.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 142
|j 2012
|e 1
|b 15
|c 01
|h 68-75
|